Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Nov 19, 2024 12:33pm
67 Views
Post# 36319998

RE:RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:RE:How does Accelerated Approval work ONCY has reported positive final results on the chosen surrogate endpoint of PFS and mOS, and therefore there are no apparent FDA restrictions on ONCY's ability to apply for an Accelerated Approval at anytime.

With an Accelerated Approval the FDA grants a conditional marketing approval and the 'condition' that a post marketing approval confirmatory trial be conducted to confirm the data of that served as the basis for the Accelerated Approval. With a positive outcome of the post approval confirmatory trial, the FDA then grants FULL APPROVAL that is consistent with the definition of a registrational study (BLA) in the normal course of  biologic drug approvals (ex. Accelerated Approval).
<< Previous
Bullboard Posts
Next >>